www.bioss.com.cn
400-901-9800
sales@bioss.com.cn
support@bioss.com.cn

Product Details

Product name:	**Anti-LAG-3 & PD-1 (Tebotelimab Biosimilar)**	**SKU:**	**BIO1000SM**
Target Name:	**LAG-3 & PD-1**	**Size:**	**100ug/ 1mg/ 5mg**
Target Uniprot:	**P18627 & Q15116**	**Concentration:**	**Lyophilized**
Clone#:	**Tebotelimab (Bispecific)**	**Isotype:**	**DART-DART-Fc**
Reactivity:	**Human**	**Calculated M.W.:**	**165.68 kDa**
Application:	**ELISA, Bioactivity: FACS, Functional assay, Research in vivo**	**Endotoxin:**	**<0.001 EU/ug**
Formulation:	**100 mM Pro-Ac 20mM Arg pH 5.0**	**Conjugation:**	**None**
Storage:	**-20°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.**	**Expression System:**	**CHO**
Reconstitution:	**Dissolve with sterile ddH₂O**	**Purification:**	**Protein A**

Data

Purity: SDS-PAGE



Anti-LAG-3 & PD-1 Reference Antibody (Tebotelimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC



The purity of Anti-LAG-3 & PD-1 Reference Antibody (Tebotelimab) is 90.76%, determined by SEC-HPLC.

ELISA



Tebotelimab bound to huLAG-3-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Tebotelimab bound to huLAG-3-CHO-K cells, and the EC50 was 8.727 nM.

ELISA



Tebotelimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Tebotelimab bound to huPD-1-Jurkatt cells, and the EC50 was 0.47 nM.

Bioactivity: FACS



Tebotelimab bound to huLAG-3-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Tebotelimab bound to huLAG-3-CHO-K cells, and the EC50 was 8.727 nM.

Bioactivity: FACS



Tebotelimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Tebotelimab bound to huPD-1-Jurkatt cells, and the EC50 was 0.47 nM.

Function: Luciferase



Co-incubation of Tebotelimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Tebotelimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 1.266 nM.